Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin and Zileuton for Lung Cancer Prevention in Smokers
NCT02348203Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2016
- Primary completion
- Feb 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lung cancer comparing Aspirin + Zileuton with Double Placebo (2 arms). Primary endpoint: Smoking-related Gene Expression Signature at 12 weeks. Started Jan 2016; status: completed.
02
Drugs
aspirinzileuton extended release
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT02348203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348203.